OSMR β Antibody (AN-A2): sc-9992

OSMR β Antibody (AN-A2) is a mouse monoclonal IgG1 kappa light chain antibody that detects OSMR β of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). OSMR β monoclonal antibody (AN-A2) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. OSMR β, also known as oncostatin M receptor β, is a critical component in signaling pathways of cytokine oncostatin M, which plays a significant role in regulating cell growth and differentiation, particularly in hematopoietic cells. OSMR β is predominantly expressed in neural cells, fibroblasts, and epithelial tumor lines, where OSMR β forms a heterodimer that interacts with interleukins to transduce signaling events initiated by oncostatin M. OSMR β significance lies not only in mediating oncostatin M effects but also in association with various pathological conditions; mutations in OSMR β gene are linked to primary cutaneous amyloidosis, an autosomal dominant disorder characterized by chronic skin itching. OSMR β ability to influence tumor cell behavior while sparing normal fibroblasts underscores OSMR β potential as a therapeutic target in cancer treatment.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

OSMR β Antibody (AN-A2) References:

1. Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor alpha, and oncostatin M receptor beta by distinct mechanisms.  |  Blanchard, F., et al. 2001. J Biol Chem. 276: 47038-45. PMID: 11602599
2. Effects of oncostatin M on human cerebral endothelial cells and expression in inflammatory brain lesions.  |  Ruprecht, K., et al. 2001. J Neuropathol Exp Neurol. 60: 1087-98. PMID: 11706938
3. Novel role of Janus kinase 1 in the regulation of oncostatin M receptor surface expression.  |  Radtke, S., et al. 2002. J Biol Chem. 277: 11297-305. PMID: 11786531
4. Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas.  |  Savarese, TM., et al. 2002. Cytokine. 17: 324-34. PMID: 12061840
5. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice.  |  Dillon, SR., et al. 2004. Nat Immunol. 5: 752-60. PMID: 15184896
6. Immunocytochemical detection and reverse transcription polymerase chain reaction expression of oncostatin M (OSM) and its receptor (OSM-Rbeta) in human fetal and adult ovaries.  |  Abir, R., et al. 2005. Fertil Steril. 83 Suppl 1: 1188-96. PMID: 15831292
7. Molecular and functional characterization of a soluble form of oncostatin M/interleukin-31 shared receptor.  |  Diveu, C., et al. 2006. J Biol Chem. 281: 36673-82. PMID: 17028186
8. Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis.  |  Arita, K., et al. 2008. Am J Hum Genet. 82: 73-80. PMID: 18179886
9. Hepatic Oncostatin M Receptor β Regulates Obesity-Induced Steatosis and Insulin Resistance.  |  Luo, P., et al. 2016. Am J Pathol. 186: 1278-92. PMID: 26976243
10. Oncostatin M receptor β deficiency attenuates atherogenesis by inhibiting JAK2/STAT3 signaling in macrophages.  |  Zhang, X., et al. 2017. J Lipid Res. 58: 895-906. PMID: 28258089
11. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta.  |  Hashimoto, T., et al. 2021. Exp Dermatol. 30: 804-810. PMID: 33428793
12. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation.  |  Mosley, B., et al. 1996. J Biol Chem. 271: 32635-43. PMID: 8999038

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-OSMR β Antibody (AN-A2) has 10 citations in a variety of scientific publications.

Primary antibodies like Anti-OSMR β Antibody (AN-A2) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

OSMR β Antibody (AN-A2) Specifications

Alternate Product Name: OSMR β

Product Clone Name: AN-A2

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: OSMR β

Epitope Species: human

Product Reactivity/Detection: OSMR β

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), FCM

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 10 citations in various scientific publications

Available Conjugates/Forms for OSMR β Antibody (AN-A2): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin